B3GALT4

Across TCGA pan-cancer cohorts, B3GALT4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated B3GALT4 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher B3GALT4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated B3GALT4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, SARC, and LUSC are the cancer types where B3GALT4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	IV	0.091	0.593	<.001	18	view →
SARC	OS	Median	All	0.022	0.861	<.001	12	view →
LUSC	OS	Median	All	0.243	0.776	.028	12	view →
PRAD	DFS	Median	All	0.085	0.774	.002	6	view →
UCEC	DFS	Median	All	1.000	0.630	.037	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

B3GALT4–CESC (OS)

Open the CESC breakdown →